BioVie Inc. - Equity Warrant

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mina Sooch. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mina Sooch has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:OCUP / Opus Genetics, Inc. President and CEO, Director 50,000
US:BIVIW / BioVie Inc. - Equity Warrant Director 813,636
US:GEMP / Gemphire Therapeutics Inc. President & CEO, Director 600,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mina Sooch. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BIVIW / BioVie Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BIVIW / BioVie Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BIVIW / BioVie Inc. - Equity Warrant Insider Trades
Insider Sales BIVIW / BioVie Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BIVIW / BioVie Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BIVIW / BioVie Inc. - Equity Warrant Insider Trades
Insider Purchases IRD / Opus Genetics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BIVIW / BioVie Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-20 OCUP Sooch Mina 12,500 2.0240 12,500 2.0240 25,300 334 6.3800 54,450 215.22
2022-05-19 OCUP Sooch Mina 12,500 2.0703 12,500 2.0703 25,879
2020-11-19 OCUP Sooch Mina 11,524 11,524

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRD / Opus Genetics, Inc. Insider Trades
Insider Sales IRD / Opus Genetics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BIVIW / BioVie Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRD / Opus Genetics, Inc. Insider Trades
Insider Purchases MTVA / MetaVia Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BIVIW / BioVie Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2016-08-10 GEMP Sooch Mina 52,500 10.0000 52,500 10.0000 525,000 730

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MTVA / MetaVia Inc. Insider Trades
Insider Sales MTVA / MetaVia Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BIVIW / BioVie Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MTVA / MetaVia Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mina Sooch as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-02-14 2022-12-27 5 OCUP Ocuphire Pharma, Inc.
Common Stock
G - Gift 50,000 50,000
2023-02-14 2022-12-27 5 OCUP Ocuphire Pharma, Inc.
Common Stock
G - Gift -100,000 296,045 -25.25
2023-02-14 2022-12-23 5 OCUP Ocuphire Pharma, Inc.
Common Stock
G - Gift -30,000 396,045 -7.04
2023-01-12 2023-01-10 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 134,456 430,501 45.42
2022-09-08 2022-09-06 4 OCUP Ocuphire Pharma, Inc.
Common Stock
X - Other 1,023 426,045 0.24 0.00 0 43
2022-05-23 2022-05-20 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 12,500 425,022 3.03 2.02 25,300 860,245
2022-05-23 2022-05-19 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 12,500 412,522 3.12 2.07 25,879 854,044
2022-02-01 2022-01-28 4 OCUP Ocuphire Pharma, Inc.
Employee Stock Option (right to buy)
A - Award 200,000 200,000
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Series B Warrant (right to buy)
P - Purchase 2,046 2,046
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Series A Warrant (right to buy)
P - Purchase 17,413 17,413
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 11,524 800,044 1.46
2020-11-13 2020-11-11 4 OCUP Ocuphire Pharma, Inc.
Employee Stock Option (right to buy)
A - Award 130,000 130,000
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Employee Stock Option (right to buy)
A - Award 158,475 158,475
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Employee Stock Option (right to buy)
A - Award 178,284 178,284
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 788,520 788,520
2019-02-05 2019-01-02 4 bivi BIOVIE INC.
Common Stock
A - Award 200,000 813,636 32.59 0.04 7,000 28,477
2018-08-14 2018-04-30 4 bivi BIOVIE INC.
common stock
A - Award 150,000 613,636 32.35 0.02 3,600 14,727
2018-08-14 2018-01-02 4 bivi BIOVIE INC.
common stock
A - Award 200,000 463,636 75.86 0.15 30,000 69,545
2018-08-14 3 bivi BIOVIE INC.
common stock
527,272
2018-08-14 3 bivi BIOVIE INC.
common stock
527,272
2018-08-14 3 bivi BIOVIE INC.
common stock
527,272
2016-11-29 2016-11-25 4 GEMP Gemphire Therapeutics Inc.
Employee Stock Option (right to buy)
A - Award 120,000 600,000 25.00
2016-10-03 2016-09-30 4 GEMP Gemphire Therapeutics Inc.
Employee Stock Option (right to buy)
A - Award 120,000 480,000 33.33
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
Series A Convertible Preferred Stock
C - Conversion -11,078 0 -100.00
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
8% Convertible Subordinated Promissory Notes
C - Conversion 0
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
Common Stock
P - Purchase 52,500 693,732 8.19 10.00 525,000 6,937,320
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
Common Stock
C - Conversion 27,141 39,431 220.84 6.71 182,005 264,420
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
Common Stock
J - Other 1,212 12,290 10.94 6.71 8,128 82,416
2016-08-12 2016-08-10 4 GEMP Gemphire Therapeutics Inc.
Common Stock
C - Conversion 11,078 11,078
2016-08-08 2016-08-04 4 GEMP Gemphire Therapeutics Inc.
Employee Stock Option (right to buy)
A - Award 360,000 360,000
2016-08-04 3 GEMP Gemphire Therapeutics Inc.
Common Stock
1,282,464
2016-08-04 3 GEMP Gemphire Therapeutics Inc.
Common Stock
1,282,464
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)